Cerenome (PSTV) EBITDA Margin (2011 - 2026)
Plus Therapeutics (PSTV) posted quarterly EBITDA Margin of 692.51% for Q1 2026, down 35861.0% year-over-year from N/an in Q1 2025, and down 64.87% quarter-over-quarter from 420.04% in Q4 2025.
Cerenome (PSTV) EBITDA Margin (2011 - 2026) Analysis & Trends
Plus Therapeutics (PSTV) has reported EBITDA Margin for 14 consecutive years, with 692.51% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA Margin fell 35861.0% year-over-year to 692.51%; the TTM figure through Mar 2026 stood at 364.36% (down 7753.0% YoY), while the FY2025 annual figure was 293.46%, down 4114.0% from the prior year.
- EBITDA Margin fell to 692.51% in Q1 2026 per PSTV's latest filing, from 420.04% in the prior quarter.
- Across five years, EBITDA Margin topped out at 78.42% in Q2 2023 and bottomed at 6978.08% in Q3 2022.
- Historically, EBITDA Margin has averaged 1056.34% across 5 years, with a median of 293.83% in 2023.
- Annual changes were most pronounced in 2023 — EBITDA Margin soared 671590 bps — and 2026, when it plunged 35861 bps.
- Plus Therapeutics' EBITDA Margin stood at 4387.4% in 2022, then soared by 93 bps to 293.83% in 2023, then climbed by 6 bps to 276.2% in 2024, then sank by 52 bps to 420.04% in 2025, then sank by 65 bps to 692.51% in 2026.
- Business Quant data shows PSTV's EBITDA Margin at 692.51% in Q1 2026, 420.04% in Q4 2025, and 320.83% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.69 Bn | 131.84 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 86.46 Bn | 78.47 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 65.62 Bn | 60.44 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.37 Bn | 53.24 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.73 Bn | 28.43 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.27 Bn | 9.87 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.23 Bn | 26.40 Bn | - | 19.75% |
| 10 | Cerenome | 28.07 Mn | 19.48 Mn | - | -2,203.65% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -692.51% |
| Dec 31, 2025 | -420.04% |
| Sep 30, 2025 | -320.83% |
| Jun 30, 2025 | -110.65% |
| Mar 31, 2025 | -333.90% |
| Dec 31, 2024 | -276.20% |
| Sep 30, 2024 | -260.92% |
| Jun 30, 2024 | -289.05% |
| Mar 31, 2024 | -196.72% |
| Dec 31, 2023 | -293.83% |
| Sep 30, 2023 | -262.18% |
| Jun 30, 2023 | -78.42% |
| Mar 31, 2023 | -944.40% |
| Dec 31, 2022 | -4,387.40% |
| Sep 30, 2022 | -6,978.08% |
| Mar 31, 2019 | -308.11% |
| Dec 31, 2018 | -134.32% |
| Sep 30, 2018 | -259.56% |
| Jun 30, 2018 | -279.70% |
| Mar 31, 2018 | -595.35% |